Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial

BACKGROUND: Type 2 diabetes (T2D) is associated with renal impairment and vascular endothelial dysfunction. Therefore, this pathological connection is an important therapeutic target. Recent cardiovascular and renal outcome trials demonstrated that sodium glucose cotransporter 2 inhibitors (SGLT2is)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Shimabukuro, Michio, Okada, Yosuke, Sugimoto, Kazuhiro, Kurozumi, Akira, Torimoto, Keiichi, Hirai, Hiroyuki, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293776/
https://www.ncbi.nlm.nih.gov/pubmed/32534578
http://dx.doi.org/10.1186/s12933-020-01065-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293776/
https://www.ncbi.nlm.nih.gov/pubmed/32534578
http://dx.doi.org/10.1186/s12933-020-01065-w

Ejemplares similares